Novamind — Investor Presentation (November 2021)
23 slides from Novamind's investor presentation, Nov 29, 2021
Slide 1: Corporate Presentation | November 2021
CSE: NM OTCQB: NVMDF FSE: HN2 November 2021
Slide 2: Disclaimer
This presentation (the “Presentation”) of Novamind Inc. (the “Company”) is current as of November 29, 2021, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors
Slide 3: Industry-leading revenue, $6M+ in FY2021
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Industry-leading revenue, $6M+ in FY20211 Specialized in ketamine-assisted psychotherapy Expanding nationally in anticipation of the FDA approving MDMA & psilocybin psychotherapy Multistate expansion underway Reid Robison, MD, MBA Chief Medic
Slide 4: Psychiatry clinics specialized in psychedelic medicine and integrative mental healthcare
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Psychiatry clinics specialized in Research sites specialized in psychedelic medicine and psychedelic clinical trials and integrative mental healthcare protocol development 4 Corporate Presentation | November 2021
Slide 5: Multistate expansion underway
Our locations Open New locations announced Head office Multistate expansion underway Additional locations will be announced in 20221 Driven by organic growth and strategic acquisitions 5 1: Unannounced locations are not included in 2022 forecast
Slide 6: Matching patients with the right treatment modalities
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Matching patients with the right treatment modalities Categories of care Potential treatment plans Diverse patient Medication management Follow up every 3-6 months population Psychotherapy Weekly sessions over three months Transcranial magnet
Slide 7: Psychedelic medicine available in our clinics
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Psychedelic medicine available in our clinics Pending FDA-approval MDMA Phase III trial, PTSD 2023 Psilocybin Phase IIb trial, depression 2025 Ketamine Spravato Depression Anxiety Major depressive disorder + suicidal ideation Suicidal ideatio
Slide 8: Operating the infrastructure required to commercialize & scale psychedelic medicine
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Operating the infrastructure required to commercialize & scale psychedelic medicine 20,000+ clinic visits in 2020 Administered 7,000+ ketamine therapy treatments1 & 5,000+ doses of Spravato2 New clinicUtah & research site3 Booking new appoint
Slide 9: 25 payor contracts, featuring 100% renewal rates
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING 25 payor contracts, featuring 100% renewal rates1 Revenue mix2 Insurance 72% Approved for direct billing of IV ketamine from four major insurance providers Opened a dedicated call center providing client care services including: Insurance ben
Slide 10: Offering access to group ketamine-assisted psychotherapy & other innovative treatments
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Offering access to group ketamine-assisted psychotherapy & other innovative treatments Hosting multi-day therapeutic experiences Leveraging Park City’s reputation as a world-class travel & wellness destination Park City, Utah 10 Corporate Pre
Slide 11: First announcement from a pipeline of accretive transactions
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING First announcement from a pipeline of accretive transactions expanding Novamind outside of Utah To be integrated with Novamind’s SOPs Founded by Jeff Edelman, who served in the US Army 55th Medical Co. Combat Stress Control unit Acquisition a
Slide 12: Phase I-IV clinical trials focused on psychedelic medicine and neuropsychiatry
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Phase I-IV clinical trials focused on psychedelic medicine and neuropsychiatry Clinical trial Patient Screening & Patient management design recruitment enrollment & data collection 12 Corporate Presentation | November 2021
Slide 13: Specialized staff and infrastructure to support psychedelic clinical trials
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Specialized staff and infrastructure to support the unique needs of psychedelic clinical trials 3 clinical research sites open DEA Schedule 1 license for psilocybin research Successful recruitment of study participants via research sites co-l
Slide 14: Research
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING 14 Corporate Presentation | November 2021
Slide 15: Expertise in pediatric and adult phase I-IV clinical trials
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Expertise in pediatric and adult phase I-IV clinical trials across a wide range of mental health conditions Hosted a pivotal ketamine study that led to the FDA- approval of Spravato by Janssen Pharmaceuticals Currently contracted for 8 clinic
Slide 16: Protocols are specific evidence-based psychotherapeutic interventions
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Protocols are specific evidence-based psychotherapeutic interventions that demonstrate improved patient outcomes Procedures for screening, preparation, dosing and integration Protocols and programs in development: Frontline Ketamine-Assisted
Slide 17: We support drug sponsors bringing innovative mental health therapies to market
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING We support drug sponsors bringing innovative mental health therapies to market Company Investment date Key information Clinical trials for ketamine, MDMA, DMT & ibogaine derivatives July 21, 2020 Early investor in Compass Pathways Selected No
Slide 18: Management team
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Yaron Conforti Reid Robison, MD, MBA Pierre Paul Thielking, MD Chief Executive Officer, Chief Medical Officer, Bou-Mansour, P.Eng. Chief Scientific Officer Director, Co-founder Director Chief Operating Officer Principal, EmmCap Corp., partici
Slide 19: Advisors
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Mirjana Allan Kaplan, MSc, MD, Craig Blinderman, Domakonda, MD FRCP(C) MD, MA Advisor Advisor Advisor Collaborator on MAPS’ MED1 study of MDMA-assisted Senior Clinician Scientist, Centre for Addiction and Director, Adult Palliative Medicine;
Slide 20: Novamind continues to lead its peer group in revenue
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Novamind continues to lead its peer group in revenue Quarterly revenue Novamind’s differentiation Among the highest revenue run-rates in the psychedelic industry Proven and replicable model for growth Revenue (C$)1 Diversified revenue streams
Slide 21: Stock performance
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Jan. 5, 2021: Began trading on the Canadian Securities Exchange Sept. 9, 2021: Uplisted to the OTCQB Venture Market Sept. 20, 2021: Included in NYSE listed AdvisorShares Psychedelics ETF Sept. 24, 2021: Received DTC eligibility Stock performa
Slide 22: Expanding nationally in anticipation of the FDA approving MDMA & psilocybin psychotherapy
INTRO • CLINICS • RESEARCH • INVESTMENTS • TEAM • CLOSING Expanding nationally in anticipation of the FDA approving MDMA & psilocybin psychotherapy Management team has a proven track record scaling healthcare organizations and high growth startups Aggressively expanding via organic growth and M&A In
Slide 23: Contact
CSE: NM OTCQB: NVMDF FSE: HN2 ir@novamind.ca